Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
March 11th, 2008
Hologic, Inc. (NASDAQ:HOLX) a diversified medical technologies company specializing in imaging systems, diagnostics, and interventional devices dedicated to serving the healthcare needs of women, announced the publication of a study evaluating the Hologic MammoSite(R) Radiation Therapy System (RTS), one-, two- and three-years after treatment. The study by Frank A. Vicini, M.D., and others, published in the February 15, 2008, issue of Cancer(1), the peer- reviewed professional journal of the American Cancer Society, reports on treatment efficacy, cosmetic results and toxicities of patients enrolled in the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry...
Source: Cancer Weekly (2008-03-11)
|
